Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology
Reference149 articles.
1. Key Statistics for Non-Hodgkin Lymphoma. American Cancer Society. 2019.
https://www.cancer.org/cancer/non-hodgkin-lymphoma/about/key-statistics.html
. Accessed 14 Mar 2019.
2. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med. 1993;328:1002–6.
3. Pferundschuh M, Trumper L, Kloess M, Schmits R, Feller AC, Rudolph C, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood. 2004;104:626–33.
4. Leoni L. Bendamustine: rescue of an effective antineoplastic agent from the mid-twentieth century. Semin Hematol. 2011;48:S4–11.
5. Garattini S. Pharmacokinetics in cancer chemotherapy. Eur J Cancer. 2007;43:271–82.